<DOC>
	<DOC>NCT00325117</DOC>
	<brief_summary>This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is designed as a multicenter, randomized, double-blind, parallel-group, placebo-controlled study aimed to evaluate the efficacy and safety of vildagliptin as add-on therapy to a sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.</brief_summary>
	<brief_title>To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis of type 2 diabetes and treated with a stable dose of sulfonylurea Patients on diet and exercise who have not reached target blood glucose levels Outpatients Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes Significant cardiovascular complications as defined by the protocol Significant diabetic complications as defined by the protocol Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>